Approximately 55% of melanoma patients exhibit intrinsic resistance to monotherapy with PD-1 inhibitors, and around 40% show intrinsic resistance to the combination of CTLA-4 and PD-1 inhibitors (139). The gene discussed is CTLA4; the disease is melanoma.